Aug 13, 2026 04:04AM

Aug 12, 2026 06:50AM

Aug 6, 2026 06:51AM

Aug 6, 2026 06:50AM

Jul 22, 2026 06:50AM

Jul 22, 2026 06:50AM

Jul 22, 2026 06:50AM Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Jul 15, 2026 05:11AM

Jul 6, 2026 06:50AM

Jul 6, 2026 06:50AM

Jun 15, 2026 06:50AM

Jun 15, 2026 06:50AM

May 12, 2026 04:05PM

May 8, 2026 06:01AM Pharvaris prices $115 million share offering at $29.68 per share

May 8, 2026 06:00AM

Apr 20, 2026 06:50AM

Apr 20, 2026 06:50AM

Apr 2, 2026 06:50AM

Mar 20, 2026 06:51AM

Mar 20, 2026 06:50AM

Mar 11, 2026 06:50AM Pharvaris publishes study validating patient outcomes in hereditary angioedema

Mar 11, 2026 06:50AM

Mar 11, 2026 06:50AM

Mar 2, 2026 06:55AM

Mar 2, 2026 06:50AM

Jan 12, 2026 06:50AM

Jan 12, 2026 06:50AM

Dec 3, 2025 06:50AM Pharvaris reports positive results from HAE treatment study

Dec 3, 2025 06:50AM

Nov 12, 2025 06:50AM

Nov 10, 2025 06:50AM

Aug 12, 2025 04:05PM

Jul 10, 2025 06:51AM

Jul 10, 2025 06:50AM

Jun 16, 2025 06:50AM Pharvaris (PHVS) Presents Data Highlighting the Potential for Deucrictibant

Jun 16, 2025 06:50AM

Jun 2, 2025 06:52AM

Jun 2, 2025 06:50AM

May 13, 2025 04:05PM

Apr 7, 2025 06:58AM

Apr 1, 2025 06:50AM

Apr 1, 2025 06:50AM Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Mar 3, 2025 06:50AM

Mar 3, 2025 06:50AM

Jan 13, 2025 06:52AM

Jan 13, 2025 06:50AM

Nov 13, 2024 04:10PM

Oct 24, 2024 08:00AM

Sep 5, 2024 06:50AM Pharvaris (PHVS) Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE

Sep 5, 2024 06:50AM

328,355 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All